TargImmune Therapeutics’ CHF 17.7 Million Financing Round

VISCHER has advised TargImmune on the deal.TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused on…

This content is for Standard 1 Year members only.
Login Join Now
Federica Tiefenthaler

Author: Federica Tiefenthaler

This content is for Standard 1 Year members only.
Login Join Now